104 related articles for article (PubMed ID: 3079417)
1. Cisplatin and new platinum analogs.
Zwelling LA
Cancer Chemother Biol Response Modif; 1987; 9():71-80. PubMed ID: 3079417
[No Abstract] [Full Text] [Related]
2. Cisplatin and new platinum analogs.
Zwelling LA
Cancer Chemother Biol Response Modif; 1988; 10():64-72. PubMed ID: 3079399
[No Abstract] [Full Text] [Related]
3. [Comparative study of the action of antineoplastic platinum compounds with varying nephrotoxic effects].
Bakhteeva VT; Fok EM; Lavrova EA
Vopr Med Khim; 1996; 42(4):301-6. PubMed ID: 9254514
[TBL] [Abstract][Full Text] [Related]
4. Platinum compounds.
Belani CP; Van Echo DA; Aisner J
Curr Opin Oncol; 1989 Dec; 1(2):186-91. PubMed ID: 2489958
[No Abstract] [Full Text] [Related]
5. Drug transporters of platinum-based anticancer agents and their clinical significance.
Burger H; Loos WJ; Eechoute K; Verweij J; Mathijssen RH; Wiemer EA
Drug Resist Updat; 2011 Feb; 14(1):22-34. PubMed ID: 21251871
[TBL] [Abstract][Full Text] [Related]
6. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
Ali BH; Al Moundhri MS
Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
[TBL] [Abstract][Full Text] [Related]
7. [Platinum derivatives].
Sasaki Y
Nihon Rinsho; 2004 Dec; 62 Suppl 12():452-5. PubMed ID: 15658361
[No Abstract] [Full Text] [Related]
8. Murine leukemia L1210 cell lines with different patterns of resistance to platinum coordination complexes.
Eastman A; Illenye S
Cancer Treat Rep; 1984 Sep; 68(9):1189-90. PubMed ID: 6541096
[TBL] [Abstract][Full Text] [Related]
9. Platinum dose-intensity.
Los G
J Infus Chemother; 1996; 6(2):64-8. PubMed ID: 8809651
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of platinum cytostatics after cisplatin-related equitoxic dosing to rats.
Amlacher R; Winnefeld K; Schröter H; Hoffmann H
Pharmazie; 1988 Nov; 43(11):798-800. PubMed ID: 3247371
[No Abstract] [Full Text] [Related]
11. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
12. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
13. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
14. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
15. [Cross resistance of a new platinum analogue, ACT-078, to CDDP and CBDCA].
Misawa T; Higashide K; Konda C; Maeda O; Hasegawa N; Kikkawa F; Tomoda Y
Gan To Kagaku Ryoho; 1995 Mar; 22(4):569-71. PubMed ID: 7887652
[No Abstract] [Full Text] [Related]
16. Clinical pharmacokinetics and administration of established platinum drugs.
O'Dwyer PJ; Stevenson JP; Johnson SW
Drugs; 2000; 59 Suppl 4():19-27. PubMed ID: 10864227
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin.
Reed E
Cancer Chemother Biol Response Modif; 1990; 11():90-6. PubMed ID: 2223411
[No Abstract] [Full Text] [Related]
18. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
20. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]